Mineralys Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLYS research report →
Companymineralystx.com
Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
- CEO
- Jon Congleton
- IPO
- 2023
- Employees
- 51
- HQ
- Radnor, PA, US
Price Chart
Valuation
- Market Cap
- $1.88B
- P/E
- -15.52
- P/S
- 0.00
- P/B
- 3.69
- EV/EBITDA
- -10.59
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.92%
- ROIC
- -26.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-154,651,000 · 13.02%
- EPS
- $-2.29 · 37.43%
- Op Income
- $-170,604,000
- FCF YoY
- 14.41%
Performance & Tape
- 52W High
- $47.65
- 52W Low
- $12.59
- 50D MA
- $27.14
- 200D MA
- $31.86
- Beta
- 0.48
- Avg Volume
- 1.20M
Get TickerSpark's AI analysis on MLYS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Rodman David Malcom | other | 417 |
| May 18, 26 | Rodman David Malcom | sell | 417 |
| May 18, 26 | Rodman David Malcom | other | 417 |
| May 13, 26 | Rodman David Malcom | other | 3,541 |
| May 13, 26 | Rodman David Malcom | other | 4,166 |
| May 13, 26 | Rodman David Malcom | other | 4,166 |
| May 12, 26 | Rodman David Malcom | other | 6,348 |
| May 13, 26 | Rodman David Malcom | other | 3,541 |
| May 11, 26 | Rodman David Malcom | other | 2,171 |
| May 12, 26 | Rodman David Malcom | sell | 6,348 |
Our MLYS Coverage
We haven't published any research on MLYS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MLYS Report →